Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...
Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
CenExel, a leading network of clinical research sites, proudly congratulates and announces its role in supporting Vertex Pharmaceuticals’ clinical studies that led to the FDA approval of JOURNAVX™ ...
Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.
The US FDA has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin.
The U.S. Food and Drug Administration has approved a new non-opioid pain medication developed by Boston-based Vertex ...
The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...
Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...
The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.
The Food and Drug Administration (FDA) is hoping a newly approved non-opioid pain medication could help save lives. Dr.
The opioid epidemic continues to affect hundreds of thousands of people, but there may be hope for the future with a new, non ...